Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing
Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Get 50% Off Elite

BLTE

Belite Bio Inc ADR

Last Close
164.35
Nov 13 • 3:59 PM ET Dollar change-5.61 Percentage change(-3.30%)
Aftermarket Close
164.35
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Overview Compare Short Interest Financials Options Filings Dilution
Healthcare Biotechnology USA Mid NASD
Nov 12, 6:38 PMBelite Bio's Stargardt NDA advances smoothly with priority review, and cash supports launch readiness
Peers: KOD OCGN ANNX OCUL IRD EYPT REGN OCS MGTX RGNX
 | Held by: SPEM APIE ONEQ GXC BBC EHLS MSSM TNXT
Scroll to Statements
Index
-
Market Cap
6.62B
Enterprise Value
6.35B
Income
-110.95M
Sales
0.00M
Book/sh
18.98
Cash/sh
6.74
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
41
IPO
Apr 29, 2022
P/E
-
Forward P/E
112.29
PEG
-
P/S
-
P/B
8.66
P/C
24.40
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
50.02
Current Ratio
50.02
Debt/Eq
0.00
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-2.83
EPS next Y
1.46
EPS next Q
-0.86
EPS this Y
-32.04%
EPS next Y
147.99%
EPS next 5Y
-
EPS past 3/5Y
-54.04% -549.64%
Sales past 3/5Y
- -
EPS Y/Y TTM
-47.46%
Sales Y/Y TTM
-
EPS Q/Q
-14.72%
Sales Q/Q
-
Earnings
Nov 12 BMO
EPS/Sales Surpr.
23.69% -
Insider Own
1.80%
Insider Trans
-20.69%
Inst Own
22.17%
Inst Trans
2.21%
ROA
-20.70%
ROE
-21.23%
ROIC
-14.40%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
7.52%
SMA50
2.16%
SMA200
2.65%
Trades
Shs Outstand
40.61M
Shs Float
39.88M
Short Float
3.46%
Short Ratio
7.39
Short Interest
1.38M
52W High
200.00 -17.82%
52W Low
105.88 55.23%
Volatility
6.89% 5.42%
ATR (14)
8.34
RSI (14)
57.28
Beta
-1.19
Rel Volume
1.16
Avg Volume
186.92K
Volume
217,014
Perf Week
6.59%
Perf Month
7.69%
Perf Quarter
0.70%
Perf Half Y
14.93%
Perf YTD
2.75%
Perf Year
46.21%
Perf 3Y
318.21%
Perf 5Y
-
Perf 10Y
-
Recom
1.00
Target Price
233.00
Prev Close
169.96
Price
164.35
Change %
-3.30%
Consensus
Strong Buy
Avg. Price Target
$233.00
Implied Upside
+41.8%
Analysts9incl. previous ratings
Rating Distribution9 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 04, 2026Initiated
CCanaccord Genuity
Buy$303+84.4%
Jan 26, 2026Initiated
BAC logoBBofA Securities
Buy$195+18.6%
Jan 06, 2026Initiated
MS logoMMorgan Stanley
Overweight$191+16.2%
Dec 02, 2025Upgrade
MFG logoMMizuho
Neutral → Outperform$194+18.0%
Nov 24, 2025Resumed
CCantor Fitzgerald
Overweight$154-6.3%
Nov 20, 2025Initiated
MFG logoMMizuho
Neutral$105-36.1%
Dec 14, 2023Initiated
MMaxim Group
Buy$60-63.5%
Jul 28, 2023Initiated
CCantor Fitzgerald
Overweight$43-73.8%
Jul 26, 2023Initiated
SSVB Securities
Outperform$25-84.8%
Aug 01, 2022Initiated
HH.C. Wainwright
Buy$58-64.7%
Show Previous News
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Scholl Hendrik PeterChief Medical OfficerOct 01 '26Sale165.3250082,65914,500Oct 05 07:27 PM
Hendrik Peter SchollOfficerOct 01 '26Proposed Sale169.824,000679,280Oct 01 06:04 PM
Lin Yu-HsinChief Executive OfficerSep 04 '26Sale187.7174,43513,972,06396,134Sep 09 07:39 PM
Lin Yu-HsinChief Executive OfficerSep 08 '26Sale196.5626,0005,110,48670,134Sep 09 07:39 PM
Chuang Hao-YuanChief Financial OfficerSep 04 '26Sale187.6449,4339,275,38944,000Sep 09 07:38 PM
Chuang Hao-YuanChief Financial OfficerSep 08 '26Sale196.4217,9623,528,13926,038Sep 09 07:38 PM
Chuang Hao-YuanChief Financial OfficerAug 12 '26Sale180.3536766,18793,433Aug 14 06:10 AM
Lin Yu-HsinChief Executive OfficerAug 12 '26Sale180.3536565,827170,569Aug 14 06:10 AM
Yu-Hsin LinCEO, ChairmanAug 12 '26Proposed Sale177.58126,80022,517,144Aug 12 05:13 PM
Hao-Yuan ChuangOfficer, DirectorAug 12 '26Proposed Sale177.5893,80016,657,004Aug 12 05:12 PM
Scholl Hendrik PeterChief Medical OfficerJun 18 '26Sale145.2410,0001,452,43515,000Jun 22 06:05 AM
Dr. Hendrick P. SchollAffiliateJun 18 '26Proposed Sale148.3410,0001,483,400Jun 18 04:27 PM
Scholl Hendrik PeterChief Medical OfficerJun 16 '26Sale140.5710,0001,405,72925,000Jun 17 06:03 AM
Dr. Hendrick P. SchollAffiliateJun 16 '26Proposed Sale144.2410,0001,442,400Jun 16 07:10 PM
MATA NATHAN L.Chief Scientific OfficerMay 07 '26Sale153.21666102,0390May 08 04:45 PM
MATA NATHAN L.Chief Scientific OfficerMay 06 '26Sale153.841,000153,839666May 07 04:15 PM
MATA NATHAN L.Chief Scientific OfficerMay 05 '26Sale155.501,000155,5021,666May 06 04:15 PM
MATA NATHAN L.Chief Scientific OfficerMay 04 '26Sale155.641,000155,6362,666May 05 04:15 PM
MATA NATHAN L.Chief Scientific OfficerMay 01 '26Sale155.781,000155,7783,666May 04 04:15 PM
MATA NATHAN L.Chief Scientific OfficerApr 30 '26Sale156.971,000156,9734,666May 01 04:15 PM
MATA NATHAN L.Chief Scientific OfficerApr 29 '26Sale155.821,000155,8175,666Apr 30 04:15 PM
MATA NATHAN L.Chief Scientific OfficerApr 28 '26Sale159.161,000159,1626,666Apr 29 04:32 PM
MATA NATHAN L.Chief Scientific OfficerApr 27 '26Sale162.641,000162,6417,666Apr 28 04:28 PM
MATA NATHAN L.Chief Scientific OfficerApr 24 '26Sale159.561,000159,5568,666Apr 27 04:52 PM
MATA NATHAN L.Chief Scientific OfficerApr 23 '26Sale166.281,000166,2849,666Apr 24 04:15 PM
MATA NATHAN L.Chief Scientific OfficerApr 22 '26Sale170.381,000170,38410,666Apr 23 04:19 PM
MATA NATHAN L.Chief Scientific OfficerApr 21 '26Sale166.001,000166,00011,666Apr 22 04:15 PM
MATA NATHAN L.Chief Scientific OfficerApr 20 '26Sale163.591,000163,59512,666Apr 21 05:28 PM
MATA NATHAN L.Chief Scientific OfficerApr 17 '26Sale161.631,000161,63013,666Apr 20 04:15 PM
MATA NATHAN L.Chief Scientific OfficerApr 16 '26Sale160.381,000160,38114,666Apr 20 04:15 PM
MATA NATHAN L.Chief Scientific OfficerApr 15 '26Sale168.301,000168,29815,666Apr 16 04:15 PM
Nathan L. MataOfficerApr 15 '26Proposed Sale171.9316,6662,865,385Apr 15 05:23 PM
Lin Yu-HsinChief Executive OfficerApr 09 '26Sale181.459,2001,669,339170,934Apr 13 04:15 PM
Chen Wan-ShanDirectorApr 09 '26Sale180.431,100198,4739,096Apr 13 04:15 PM
Chuang Hao-YuanChief Financial OfficerApr 09 '26Sale181.506,2001,125,30393,800Apr 13 04:15 PM
Yu-Hsin LinCEO, ChairmanApr 09 '26Proposed Sale178.73136,00024,307,280Apr 09 04:52 PM
Hao-Yuan ChuangOfficer, DirectorApr 09 '26Proposed Sale178.73100,00017,873,000Apr 09 04:43 PM
Wan Shan ChenaffiliateApr 09 '26Proposed Sale217.7610,1962,220,250Apr 09 12:17 PM
Belite Bio, Inc. engages in the research and development of drugs. It focuses on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.
Ph.D.Dr. Yu-Hsin Lin M.B.A.
F.R.M.Mr. Hao-Yuan Chuang C.F.A.
Chief Scientific OfficerDr. Nathan L. Mata Ph.D.
M.D.Dr. Hendrik P.N. Scholl M.A.
Chief Commercial OfficerMs. Kelly Kilpatrick
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)